Core Viewpoint - The article discusses the evolving landscape of the medical device industry in China, highlighting the importance of business development (BD) strategies that go beyond mere numbers to encompass strategic partnerships, market expansion, and technological integration [1][24]. Group 1: Key Trends in Medical Device BD - The primary keywords for the period from July to September include cross-border introduction and global distribution, strategic cooperation, and capital and cross-industry integration [2]. - Companies are accelerating market expansion and ecosystem building through transactions across various fields, including cardiovascular, neuro-intervention, ophthalmology, IVD, and critical care [3]. Group 2: Representative Events - A total of 20 significant events were summarized, showcasing a "multi-line advancement" scenario in the industry [4]. - Notable collaborations include: - Nanjing Jianxin Medical and Heqi Family Office focusing on medical device R&D and wealth management [6]. - Olympus and Xingchenhai Medical signing a global distribution agreement for disposable urology products [6]. - He’s Eye Group and Zeiss China Medical forming a strategic partnership to enhance ophthalmic surgical technology [6]. Group 3: Cross-Border and Global Distribution - Cross-border transactions remain a hot topic, with domestic companies leveraging global markets for growth while foreign giants introduce Chinese innovations [9]. - The partnership between Ruichao Dinkai Group and Beijing Amite focuses on vascular intervention products, marking a new phase in safety standards [7]. Group 4: Strategic Cooperation and Channel Expansion - Strategic cooperation is increasingly focused on building ecosystems rather than single product breakthroughs, with companies forming partnerships in fields like ophthalmology, IVD, and diagnostics [19]. - The collaboration between Wanfu Biological and Beiden Medical aims to match products with non-public medical channels effectively [15]. Group 5: Capital Support and Cross-Industry Integration - Capital is becoming an invisible driver of medical device BD, with partnerships exploring new models for medical device distribution [20]. - The collaboration between Beijing Huamai Supply Chain Management and Hongyi Consulting aims to create a one-stop service for medical device distribution [20]. Group 6: Smart Hospitals and Full-Chain Coordination - The focus on smart hospitals and full-chain coordination is becoming a priority for large enterprises, integrating supply chains, academic promotion, and clinical needs [23]. - Collaborations like that of Ruibo Zehou Technology and China National Pharmaceutical Group aim to develop automated systems for smart hospitals [21]. Conclusion - The medical device industry in China is transitioning from a "single product-driven" phase to a more diversified approach supported by capital, channels, and ecosystems, indicating a long-term growth trajectory [24].

Core Insights - The partnership between Peijia Medical's subsidiary, Gaqi Bio, and Yanqi Medical aims to enhance the market promotion, sales, and after-sales service of the "Qida® Disposable Neurovascular Sheath" across China, establishing a strategic collaboration in the neuro-intervention field [1][3] - The "Qida®" product, designed specifically for stroke intervention surgeries, received its medical device registration certificate in February 2024 and integrates multiple technological innovations to meet clinical needs [2][3] - Gaqi Bio has built a strong reputation in the neuro-intervention sector through its mature market network and professional academic promotion capabilities, while Yanqi Medical focuses on innovative research and development [3] Product Details - The "Qida®" sheath features a large lumen design of 0.088 inches, allowing flexibility for various catheter systems used in complex surgical procedures [2] - Its multi-segment transitional structure ensures proximal stability while enhancing overall passability, making it suitable for tortuous vascular environments [2] - The distal 4 cm soft segment design adapts to vascular shapes, ensuring safe access to distal lesions, and the 45° head design facilitates rapid establishment of a reliable surgical access system [2] Future Collaboration - Both companies expressed intentions to deepen collaboration in technology development, market promotion, and service system construction, focusing on clinical needs to drive innovation and product upgrades in the neuro-intervention field [3]